甲氨蝶呤治疗伴或不伴银屑病关节炎的中国成人银屑病的安全性与疗效
这项前瞻性单臂干预研究纳入235例中国银屑病患者(不伴关节炎107例,伴关节炎128例),给予12周低剂量口服甲氨蝶呤(每周7.5-15 mg)。伴关节炎组在第8周和第12周的PASI 90应答率均显著低于不伴关节炎组,且头晕、胃肠道症状和肝毒性发生率显著更高。作者认为甲氨蝶呤对不伴关节炎的银屑病更有效且不良反应更少,可推荐作为无关节炎银屑病的一线治疗。
要点
- 伴关节炎组第12周PASI 90应答14.8%(19/128),不伴关节炎组25.2%(27/107),P=0.049。
- 伴关节炎组头晕9.4%(12/128) vs 不伴关节炎组0.9%(1/107),P=0.007。
- 伴关节炎组胃肠道症状25.0%(32/128) vs 不伴关节炎组12.1%(13/107),P=0.01。
核心结论
- 甲氨蝶呤治疗银屑病耐受良好且有效,对不伴银屑病关节炎的患者比伴关节炎者更有效且不良反应更少,作者因此推荐甲氨蝶呤作为无关节炎银屑病的一线治疗。
研究设计与样本
- 前瞻性单臂干预研究,2015年4月1日至2017年12月31日从中国一所大型大学医院门诊招募235例银屑病患者,其中不伴银屑病关节炎107例、伴银屑病关节炎128例。
- 干预为12周疗程的低剂量口服甲氨蝶呤(每周7.5-15 mg)。
主要发现
- 第8周PASI 90应答率伴关节炎组3.1%(4/128) vs 不伴关节炎组11.2%(12/107),P=0.02;第12周伴关节炎组14.8%(19/128) vs 不伴关节炎组25.2%(27/107),P=0.049。
- 不良反应发生率伴关节炎组 vs 不伴关节炎组:头晕9.4%(12/128) vs 0.9%(1/107),P=0.007;胃肠道症状25.0%(32/128) vs 12.1%(13/107),P=0.01;肝毒性26.6%(34/128) vs 15.0%(16/107),P=0.04。
- 甲氨蝶呤诱导的丙氨酸氨基转移酶升高与体重指数相关(伴关节炎组均值[SD] 26[4],P=0.04;不伴关节炎组26[4],P=0.005),也与吸烟相关(伴关节炎组17/34[50.0%],P=0.02;不伴关节炎组9/16[56.3%],P=0.04)。
临床怎么用
- 作者认为甲氨蝶呤可推荐作为不伴关节炎的银屑病的一线治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: It is necessary to determine whether psoriasis responds to methotrexate in the same manner in patients with and without psoriatic arthritis. OBJECTIVE: To evaluate the effectiveness and safety of methotrexate in treating patients with psoriasis with and without psoriatic arthritis. DESIGN, SETTING, AND PARTICIPANTS: In this prospective, single-arm, interventional study, a total of 235 patients with psoriasis, 107 without psoriatic arthritis and 128 with psoriatic arthritis who were receiving methotrexate therapy from April 1, 2015, to December 31, 2017, were recruited from the outpatient department of a hospital at a large Chinese university. There were no significant demographic or clinical differences between the subgroups with the exception of diabetes. INTERVENTIONS: A 12-week course of low-dosage oral methotrexate (7.5-15 mg weekly). MAIN OUTCOMES AND MEASURES: Changes in disease severity, adverse events, blood cell counts, and liver and renal function. RESULTS: A total of 235 patients with psoriasis (166 male [66.0%]; mean [SD] age, 49.6 [15.1] years) received methotrexate treatment for 12 weeks. The 90% reduction from baseline Psoriasis Area Severity Index response was significantly lower in patients with psoriatic arthritis than in patients without psoriatic arthritis at week 8 (4 0f 128 [3.1%] vs 12 of 107 [11.2%]; P = .02) and week 12 (19 of 128 [14.8%] vs 27 of 107 [25.2%]; P = .049). Furthermore, the incidence of adverse events, including dizziness (12 of 128 [9.4%] vs 1 of 107 [0.9%]; P = .007), gastrointestinal symptoms (32 of 128 [25.0%] vs 13 of 107 [12.1%]; P = .01), and hepatoxicity (34 of 128 [26.6%] vs 16 of 107 [15.0%]; P = .04), was significantly higher in patients with psoriatic arthritis than in patients without psoriatic arthritis. Methotrexate-induced elevation of alanine aminotransferase levels was associated with body mass index (mean [SD] body mass index, 26 [4] in patients with [P = .04] vs 26 [4] in those without [P = .005] psoriatic arthritis) and smoking (17 of 34 [50.0%] in patients with [P = .02] vs 9 of 16 [56.3%] in those without [P = .04] psoriatic arthritis). CONCLUSIONS AND RELEVANCE: In this study, methotrexate was well tolerated and effective in treating psoriasis. It was more effective, with fewer adverse effects, in patients with psoriasis who did not have psoriatic arthritis than in patients who presented with both psoriasis and psoriatic arthritis. Therefore, methotrexate can be recommended as first-line treatment for psoriasis without arthritis.
引用
- Yan K, Zhang Y, Han L, et al. Safety and Efficacy of Methotrexate for Chinese Adults With Psoriasis With and Without Psoriatic Arthritis. JAMA Dermatol. 2019. PMID: 30698628. doi:10.1001/jamadermatol.2018.5194
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。